Home › Funds › First Washington CORP › VKTX

First Washington CORP position in VKTX

VIKING THERAPEUTICS INC · Health Care

First Washington CORP reported holding 378,757 shares of VKTX (VIKING THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$12.3M, representing 3.38% of its reported portfolio and ranking #5 among its reported holdings. First Washington CORP has disclosed VKTX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)378.76K sh
Reported value held$12.35M
Portfolio Weight3.38%
First reportedQ4 2023
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How First Washington CORP's VKTX position evolved

First Washington CORP first disclosed a stake in VKTX in Q4 2023 at 239,310 shares (US$4.5M). The position peaked in Q2 2026 at 381,300 shares, worth US$14.9M. Across 12 filings, First Washington CORP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 378,757 shares valued at US$12.3M — a reduction of -2,543 shares quarter over quarter.. Notable position changes include a 96% trim in Q1 2024 (shares fell 35% over the following quarter), a 316% increase in Q2 2024 (shares rose 19% over the following quarter), a 151% increase in Q3 2025 (shares rose 34% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 239.31K $4.45M New
Q1 2024 9.54K $782.12K Reduce
Q2 2024 39.69K $2.10M Add
Q3 2024 59.12K $3.74M Add
Q4 2024 59.12K $2.38M Hold
Q1 2025 106.48K $2.57M Add
Q2 2025 106.48K $2.82M Hold
Q3 2025 266.84K $7.01M Add
Q4 2025 387.53K $13.63M Add
Q1 2026 385.37K $12.54M Reduce
Q2 2026 381.30K $14.87M Reduce
Q3 2026 378.76K $12.35M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VKTX and 13F data

VKTX (VIKING THERAPEUTICS INC) is a Health Care company. 30 other funds we track also report a position in VKTX — the largest reported positions include Context Capital Management, LLC (US$39.9M), Vestal Point Capital, LP (US$26.5M), Eversept Partners, LP (US$23.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VKTX

All VKTX fund holders →

FAQ

How long has First Washington CORP held VKTX?

First Washington CORP has disclosed VKTX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is First Washington CORP's current position in VKTX?

As of Q3 2026, First Washington CORP holds 378.76K shares of VKTX (VIKING THERAPEUTICS INC), valued at $12.35M, representing 3.38% of its reported portfolio and ranking #5.

Has First Washington CORP been buying or selling VKTX?

In the latest 13F filing (Q3 2026), First Washington CORP reduced its position in VKTX. The position peaked in Q2 2026 at 381.30K shares.

Which other funds hold VKTX?

Other major institutional holders of VKTX include Context Capital Management, LLC, Vestal Point Capital, LP, Eversept Partners, LP, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.